These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37668187)

  • 21. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.
    Ohya Y; Makihara N; Wakisaka K; Morita T; Ago T; Kitazono T; Takaba H
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):e128-e131. PubMed ID: 29555397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dabigatran Reversal with Idarucizumab in an Emergency Lumbar Puncture: A Case Report.
    Spagnolello O; Letteri F; Falcou A; Cipollone L; De Michele M; Bertazzoni G; Toni D
    Curr Drug Saf; 2019; 14(1):40-42. PubMed ID: 30112997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of dabigatran with idarucizumab in hyperacute stroke: a new paradigm?
    Ting A; Venkat AR; Gawarikar Y; Patel R
    Med J Aust; 2019 Apr; 210(7):302-303.e1. PubMed ID: 30924530
    [No Abstract]   [Full Text] [Related]  

  • 25. Kidney dysfunction has a major impact on the effect of idarucizumab for dabigatran reversal.
    Athavale A; Jamshidi N; Roberts DM
    Eur J Anaesthesiol; 2021 Sep; 38(9):1005-1006. PubMed ID: 34397529
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
    Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
    J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.
    Ng FC; Bice J; Rodda A; Lee-Archer M; Crompton DE
    J Neurol; 2017 Mar; 264(3):591-594. PubMed ID: 28168523
    [No Abstract]   [Full Text] [Related]  

  • 29. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
    Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early-access programme in emergency care: idarucizumab use for rapid dabigatran reversal in critical care patients.
    Elalamy I; Crisan O; Gruenenfelder F; Benarousse G; Tazarourte K
    Eur J Emerg Med; 2019 Jun; 26(3):230-231. PubMed ID: 31033622
    [No Abstract]   [Full Text] [Related]  

  • 31. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
    Levy JH; van Ryn J; Sellke FW; Reilly PA; Elsaesser A; Glund S; Kreuzer J; Weitz JI; Pollack CV
    Ann Surg; 2021 Sep; 274(3):e204-e211. PubMed ID: 31599808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran Reversal with Idarucizumab.
    Pollack CV; Reilly PA; Weitz JI
    N Engl J Med; 2017 Oct; 377(17):1691-2. PubMed ID: 29069562
    [No Abstract]   [Full Text] [Related]  

  • 36. Idarucizumab: First Global Approval.
    Burness CB
    Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
    Tireli D; He J; Nordling MM; Wienecke T
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
    Lindeman E
    Lakartidningen; 2017 Dec; 114():. PubMed ID: 29292966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure.
    Stecher A; Vene N; Mavri A; Mijovski MB; Krevel B; Gradišek P
    Eur J Anaesthesiol; 2017 Jun; 34(6):400-402. PubMed ID: 28459790
    [No Abstract]   [Full Text] [Related]  

  • 40. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.